COMMUNIQUÉS West-GlobeNewswire

-
NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services
22/01/2024 - 13:00 -
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
22/01/2024 - 13:00 -
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
22/01/2024 - 12:50 -
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
22/01/2024 - 12:45 -
Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024
22/01/2024 - 12:30 -
Bionomics Provides a Review of 2023 and of 2024 Plans
22/01/2024 - 12:00 -
Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)
22/01/2024 - 12:00 -
Sosei Heptares Webinar Presentation for FY2023 Financial Results
22/01/2024 - 10:30 -
Calibre Scientific Acquires RUWAG, a Swiss Provider of Diagnostics and Life Sciences Products and Services
22/01/2024 - 10:00 -
Calibre Scientific fait l’acquisition de RUWAG, un fournisseur suisse de produits et de services pour le diagnostic et les sciences de la vie
22/01/2024 - 10:00 -
ProteinLogic and Stellenbosch University receive $1.3 million grant to develop blood test to monitor response to TB antimicrobial chemotherapy
22/01/2024 - 09:00 -
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
22/01/2024 - 07:15 -
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
22/01/2024 - 07:00 -
InkSpace Imaging Announces Dr. E. Brian Welch, PhD, MBA as Vice President of Clinical Partnerships
20/01/2024 - 03:53 -
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
19/01/2024 - 23:15 -
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
19/01/2024 - 22:15 -
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/01/2024 - 22:05 -
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/01/2024 - 22:01 -
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/01/2024 - 22:00
Pages